

**BILL SUMMARY**  
1<sup>st</sup> Session of the 60<sup>th</sup> Legislature

<b>Bill No.:</b>	<b>HB1380</b>
<b>Version:</b>	<b>CS</b>
<b>Request Number:</b>	<b>12956</b>
<b>Author:</b>	<b>Rep. Dempsey</b>
<b>Date:</b>	<b>2/27/2025</b>
<b>Impact:</b>	<b>OSDH: FY26: \$24,362.50</b> <b>FY27+: \$9,745</b>

**Research Analysis**

Pending

Prepared By: House Research Staff

**Fiscal Analysis**

The committee substitute to HB 1380 establishes the Insulin Access and Affordability Program within the State Department of Health (OSDH) to lower insulin prices, address generic drug shortages, and improve access to affordable drugs. OSDH is authorized to enter into agreements with nonprofit pharmaceutical companies registered with the FDA and other nonprofit organizations to implement the program.

According to OSDH officials, the measure would require:

- **Programmatic staff** to consult with other states that have implemented similar programs, identify nonprofit(s) to enter memoranda of understanding or contracts, ensure contractor(s) meet specified requirements (contract monitoring)
  - FY26: .25 FTE for the first year - \$24,362.50 (salary and fringe)
  - FY27+: .1 FTE for subsequent years - \$9,745 (salary and fringe)
- **Legal staff** to review memoranda of understanding language and contracts
  - OSDH would absorb in current workload
- **Contractor fees**
  - Cost is unknown at this time, but could be significant

Therefore, the fiscal impact on the FY26 state budget is estimated to be a minimum of \$24,362.50, with potential for higher costs depending on contractor fees.

Prepared By: Alexandra Ladner, House Fiscal Staff

**Other Considerations**

None.

